Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott acquires Aventis’ Mavik

Executive Summary

Abbott Labs acquires full manufacturing and commercial rights to Aventis' cardiovascular drugs Mavik and Tarka for $300 mil. plus royalties. Abbott already holds marketing rights to Mavik (trandolapril) and Tarka (trandolapril/verapamil) in the U.S. and other countries under a 1991 licensing deal. Aventis will retain rights to the products in Japan. Combined global sales topped $200 mil. in 2003; Abbott believes sales of the two drugs could eventually reach $700 mil. The divestiture is not related to the Sanofi merger, Aventis says...

You may also be interested in...



Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued

In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.

Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Swiss Initiative To Monitor Missing Medical Devices To Manage Current Product Crisis

The ongoing availability of many medical devices in Switzerland is threatened even more severely than in the EU. Medtech Insight spoke to two key life science experts to understand why this is and to hear the solutions they are proposing.

Latest News
See All
UsernamePublicRestriction

Register

PS044097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel